

**BIOLOGICAL HEALTH RISKS
QUALITY OF LABORATORIES**

CLINICAL BIOLOGY COMMISSION

**EXTERNAL QUALITY ASSESSMENT
IN CLINICAL BIOLOGIE**

PRELIMINARY REPORT

Molecular Microbiology

HCV-HBV

Pilot Study

SURVEY 2022/6

Expected results :

HCV

Sample ID	Matrix	Content	Qualitative result	Quantitative result* (Log IU/mL)
HCV22-1	plasma	HCV	Positive	3.2
HCV22-2	plasma	HCV	Positive	3.83
HCV22-3	plasma	HCV	Positive	3.39
HCV22-4	plasma	HCV	Positive	3.7
HCV22-5	plasma	No HCV	Negative	Not applicable

* : it is the value obtained by the NRC during the validation of the panel

HBV

Sample ID	Matrix	Content	Qualitative result	Quantitative result* (Log IU/mL)
HBV22-1	plasma	HBV	Positive	5.44
HBV22-2	plasma	HBV	Positive	5.26
HBV22-3	plasma	HBV	Positive	4.62
HBV22-4	plasma	HBV	Positive	4.07
HBV22-5	plasma	No HBV	Negative	Not applicable

* : it is the value obtained by the NRC during the validation of the panel

Authorization of the report:



Bernard China

By Bernard China, scheme coordinator
Sciensano – Service Quality of laboratories
J. Wytmanstreet, 14 | 1050 Brussels
Tel.: 02/6425385 E-mail : bernard.china@sciensano.be.

Date of publication: 06/10/2022

© Sciensano Brussels 2022.

This report may not be reproduced, published or distributed without the consent of Sciensano. The laboratories' individual results are confidential. They are not passed on by Sciensano to third parties, nor to members of the Commission, the committees of experts or the working group EQA.

END